Abstract
Hodgkin’s lymphoma is a rare yet highly curable disease in the majority of patients treated with modern chemotherapy regimens. For patients who fail to respond to or relapse after initial systemic therapies, treatment with high-dose chemotherapy and autologous hematopoietic stem cell transplantation can provide a cure for many with chemotherapy-responsive lymphoma. Patients who relapse after autologous transplant or those with chemorefractory disease have poor prognosis and represent a high unmet need. Allogeneic hematopoietic stem cell transplantation provides a proven curative therapy for these patients and should be considered, especially in young and medically fit patients. The use of newer agents in this disease such as brentuximab vedotin and immune checkpoint inhibitors can help bring more patients to transplantation and should be considered as well.
Original language | English (US) |
---|---|
Article number | 125 |
Journal | Journal of Personalized Medicine |
Volume | 12 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2022 |
Keywords
- Allogeneic hematopoietic stem cell transplant
- Autologous hematopoietic stem cell transplant
- High-dose chemotherapy
- Hodgkin’s lymphoma
ASJC Scopus subject areas
- Medicine (miscellaneous)